The PfGAP3KO genetically-attenuated parasite vaccine clinical trial is now published in Science Translational Medicine. In this study, participants were immunized three or five times with ~200 mosquito bites per dose containing the PfGAP3KO vaccine. Later, the participants underwent controlled human malaria infection and half of vaccinated participants were protected. The study shows the promise of GAP vaccines and paves the way for additional research to translate these findings to an even more efficacious and deployable vaccine. Thanks to the many partners involved in this study and to the volunteers for their generous participation in this study.
Comments are closed.
|
Lab PostUpdates about lab activities, papers and other insights! Archives
April 2024
Categories |